Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.
Simple Summary: Capivasertib is a selective AKT kinase inhibitor recently approved for the treatment of estrogen receptor-positive/HER2-negative advanced BC with alterations of the PIK3CA/AKT1/PTEN pathway, in combination with fulvestrant after progression on endocrine therapy. In this review we sum...
| Publicado en: | Current Oncology Vol. 33; no. 4; pp. 198 - 218 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Apr2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=193441191&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 193441191 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Apr2026 vid: 33 iid: 4 pid: 97109 pub: MDPI artinfo: ui: 193441191 10.3390/curroncol33040198 193441191 ppf: 198 ppct: 20 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review. aug: au: Valerio, Maria Rosaria Sambataro, Daniela Martorana, Federica Greco, Martina Mesi, Chiara Gebbia, Vittorio Vigneri, Paolo Scandurra, Giuseppa affil: Medical Oncology Unit, Policlinico, University of Palermo, 90100 Palermo, Italy sug: ab: Simple Summary: Capivasertib is a selective AKT kinase inhibitor recently approved for the treatment of estrogen receptor-positive/HER2-negative advanced BC with alterations of the PIK3CA/AKT1/PTEN pathway, in combination with fulvestrant after progression on endocrine therapy. In this review we summarize preclinical evidence, pharmacology, clinically relevant problems, practical management and future options related to capivasertib. Most patients with advanced/metastatic hormone receptor-positive, HER2-negative breast cancer receive first-line therapy with cycline-dependent kinase 4/6 inhibitors plus endocrine therapy. Almost universally, these patients eventually progress due to the emergence of resistant cancer clones. Targeting the PIK3CA/AKT1/PTEN pathway is a way of overcoming resistance. Recently, the oral, selective AKT kinase inhibitor capivasertib has been approved for the treatment of estrogen receptor-positive/human HER2-growth factor receptor-2 advanced BC with alterations in PIK3CA/AKT1/PTEN, in combination with fulvestrant after progression on endocrine therapy. We performed a narrative review to recapitulate the available evidence about capivasertib in the management of advanced hormone receptor-positive, HER2-negative breast cancer, focusing on studies that address preclinical rationale, pharmacology, and clinically relevant problems. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|